Drug Development/R&D
New medicines lead to improved patient outcomes and societal benefits, but R&D is a long and costly process. Ongoing health economics research aims to find the right balance between incentivising manufacturers to innovate and ensuring affordable access for health systems.
R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C
1 July 2018
Using a multidisciplinary methodological approach combining a theoretical economic framework with uptake/market share analyses by country and interviews, this OHE research concludes that: (i) IP incentives…
Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help? A Summary of a Symposium held at HTAi Rome 2017
31 October 2017
OHE has just published a new briefing entitled ‘Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help?’
Opportunities for Utilising ‘Real World Data’ in South Korea
20 October 2017
OHE publishes a report assessing the capacity in South Korea for the collection and use of real-world data in health care.
OHE Lunchtime Seminar: The UK Biotech Sector and Brexit: Past Performance and Future Prospects
25 September 2017
OHE Lunchtime Seminar with Sir Geoffrey Owen and Professor Michael Hopkins. The biotech sector of the US has enjoyed a success that the UK sector has…
An Insurance Framework for Funding New Antibiotics
22 September 2017
A new paper sets out an insurance model as part of a global solution to incentivise R&D for new antibiotics to tackle multi-drug resistance. It offers…
Postdoctoral Position in The Economics of Life Sciences R&D
27 June 2017
The Structural Genomics Consortium Oxford, University of Oxford, in collaboration with OHE (Prof Adrian Towse) and Dr Jorge Mestre-Ferrandiz, is recruiting for a Postdoctoral Position in…
Professor Dame Sally Davies: Ten Years of the NIHR: Achievements and Challenges for the Next Decade
15 June 2017
In November 2016 Professor Dame Sally Davies delivered the 23rd OHE Annual Lecture on the topic of: Ten Years of the NIHR: Achievements and Challenges for…
Assessing the Value of New Antibiotics: Additional Elements of Value for Health Technology Assessment Decisions
30 May 2017
Without new antibiotics, more patients will die from previously treatable infections. A key issue is how the value of antibiotics can be appropriately assessed by payers…
New Publication: ‘Macro’ Evaluation of the NIHR Oxford Biomedical Research Centre
22 May 2017
OHE and RAND Europe were commissioned by the Oxford BRC to undertake a programme of top-down evaluations of aspects of the impact of the BRC. This…